Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2020 financial results before the regular market hours on Tuesday. The pharmaceutical giant reported fourth-quarter revenue of $22.5 billion, up 8% year-over-year, and higher than the Wall Street projection. Net income of $1.86 per share also topped the target that analysts had anticipated.
JNJ shares rose 1.8% immediately following the announcement. The stock has gained 11% in the trailing 12 months.

“We continue to progress our COVID-19 vaccine candidate and look forward to sharing details from our Phase 3 study soon. Johnson & Johnson was built for times like these, and I am extremely confident in our ability to deliver lasting value and continued innovation in 2021 and for years to come,” CEO Alex Gorsky said in a statement.
Prior performance
Most Popular
Earnings calendar for the week of March 8
On the heels of lawmakers moving closer to passing the stimulus bill, inflations concerns gripped the market after Federal Reserve chief Jerome Powell at a meeting said the reopening would
Why Costco’s (COST) growth prospects might depend on beating costs, digital lag
Though the retail boom triggered by the pandemic was estimated to be short-lived initially, the shopping spree continued as customers stocked up on essential items, concerned about the persistent market
Gap (GPS) hopes to see a favorable recovery by the second half of 2021
Shares of Gap Inc. (NYSE: GPS) were up 5.8% in afternoon hours on Friday. The stock has gained 103% over the past 12 months. Gap reported mixed results for the